Sevillano Prieto, Ángel Manuel Hernández Martínez, Eduardo González Monte, Esther Mateo Bernardo, Isabel Gutiérrez Martínez, Eduardo Morales Ruiz, Enrique Praga Terente, Manuel
Anakinra induce la remisión completa del síndrome nefrótico en un paciente con fiebre mediterránea familiar y amiloidosis. [caso clínico] - Nefrología : publicación oficial de la Sociedad Española Nefrologia, 2016 - 36(1):63-6.
Formato Vancouver:
Sevillano ÁM, Hernandez E, Gonzalez E, Mateo I, Gutierrez E, Morales E, Praga M. Anakinra induce la remisión completa del síndrome nefrótico en un paciente con fiebre mediterránea familiar y amiloidosis. Nefrologia. 2016;36(1):63-6.
PMID: 26409501
Contiene 29 referencias
Renal amyloidosis is one of the most severe complications of familial Mediterranean fever (FMF). Colchicine has reduced the incidence of this complication, which now only appears in untreated, under-treated and resistant patients, but it is usually ineffective in patients with advanced amyloidosis. Here we report a patient with FMF and biopsy-proven amyloidosis who presented with nephrotic syndrome despite colchicine treatment. Anakinra (an interleukin-1β inhibitor) was started and a dramatic complete remission of nephrotic syndrome was observed in the following months. Anakinra can be an effective treatment for FMF patients with severe secondary amyloidosis.
Anakinra induce la remisión completa del síndrome nefrótico en un paciente con fiebre mediterránea familiar y amiloidosis. [caso clínico] - Nefrología : publicación oficial de la Sociedad Española Nefrologia, 2016 - 36(1):63-6.
Formato Vancouver:
Sevillano ÁM, Hernandez E, Gonzalez E, Mateo I, Gutierrez E, Morales E, Praga M. Anakinra induce la remisión completa del síndrome nefrótico en un paciente con fiebre mediterránea familiar y amiloidosis. Nefrologia. 2016;36(1):63-6.
PMID: 26409501
Contiene 29 referencias
Renal amyloidosis is one of the most severe complications of familial Mediterranean fever (FMF). Colchicine has reduced the incidence of this complication, which now only appears in untreated, under-treated and resistant patients, but it is usually ineffective in patients with advanced amyloidosis. Here we report a patient with FMF and biopsy-proven amyloidosis who presented with nephrotic syndrome despite colchicine treatment. Anakinra (an interleukin-1β inhibitor) was started and a dramatic complete remission of nephrotic syndrome was observed in the following months. Anakinra can be an effective treatment for FMF patients with severe secondary amyloidosis.
